Indivior Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. (ticker INDV) is a U.S.-listed specialty pharmaceutical company traded on the Nasdaq, not the NYSE. Headquartered in North Chesterfield, Virginia, in the United States, the company has built a focused position in medications for opioid use disorder (OUD) and related addiction-treatment services. Its modern corporate history dates to 2014, when Reckitt Benckiser spun off its specialty pharmaceuticals business into a standalone entity. More recently, Indivior completed a redomiciliation from the United Kingdom to the United States in January 2026, with Indivior Pharmaceuticals, Inc. becoming the new Delaware parent company. Indivior’s business model is centered on prescription treatments for substance use disorder, with a clear emphasis on OUD. The flagship product is SUBLOCADE, a once-monthly extended-release buprenorphine injection used to treat moderate to severe OUD. The company also markets SUBOXONE, a buprenorphine/naloxone sublingual film, and OPVEE, a nalmefene nasal spray designed for emergency reversal of suspected opioid overdose. The company’s product portfolio includes additional formulations and some non-U.S. products, but the investment case is increasingly anchored in the U.S. SUBLOCADE franchise, which has become the dominant revenue driver. From a competitive standpoint, Indivior occupies a specialized and defensible niche in a market shaped by clinical need, regulation, reimbursement, and public-health policy. The company has longstanding experience in addiction medicine, established relationships with prescribers and treatment centers, and a regulatory framework that supports controlled distribution and patient safety. At the same time, it faces meaningful pressure from generic competition on legacy products, pricing and access constraints from payers, and the need to continually expand awareness among patients and healthcare providers. The strategic picture is therefore one of concentration: fewer core assets, but a stronger emphasis on the flagship long-acting injectable product. Recent developments have been important for investors. Indivior reported higher 2025 SUBLOCADE revenue, stronger profitability, and a simplified operating model. Management also launched a direct-to-consumer campaign to broaden awareness of SUBLOCADE, settled an older DOJ matter in November 2025, and authorized a new $400 million share repurchase program. In December 2025, the company was added to the S&P SmallCap 600, improving index visibility. For French-speaking investors following U.S. healthcare names, INDV is best viewed as a specialized addiction-treatment platform on the Nasdaq in the United States, with a concentrated product mix, meaningful execution leverage, and a valuation story tied closely to SUBLOCADE growth and disciplined capital allocation.